The Claim

Empagliflozin reduces the secretion of pro-inflammatory cytokines IL-6 and MCP-1 from human epicardial adipocytes in vitro.

Source: Empagliflozin suppresses the differentiation/maturation of human epicardial preadipocytes and improves paracrine secretome profile

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
32score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

Empagliflozin decreases the release of inflammatory signaling molecules IL-6 and MCP-1 from fat cells surrounding the heart in laboratory experiments.

See the scientific wording

Empagliflozin reduces the secretion of pro-inflammatory cytokines IL6 and MCP1 from human epicardial adipocytes in vitro, suggesting a modulation of the adipose tissue secretome.

Why this might work

Empagliflozin blocks a protein called SGLT2 in immature heart fat cells, preventing them from fully developing into mature fat cells. This stops the cells from producing and releasing high levels of inflammatory signals IL-6 and MCP-1.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Empagliflozin suppresses the differentiation/maturation of human epicardial preadipocytes and improves paracrine secretome profile

    The study found that a diabetes drug called empagliflozin makes heart fat cells release less of two inflammatory proteins (IL6 and MCP1), exactly as the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.